Immix Biopharma · pitchdeck
Immix Biopharma | Investor Presentation Deck | 56 slides
56 pages · 4 arc beats · 2 loops
Immix Biopharma | Investor Presentation Deck | 56 slides
Immix Biopharma · 2024-03 arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
12468101214161820222426283032343638404244464850525456
Deck intelligence map
4 coverage by narrative range · generated from this deck JSON
Narrative range 10 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Problem 1 slides 100% 1/1 slides 100% 1/1 slides · 4 hits — 0/1 slides
— 0/1 slides
100% 1/1 slides 100% 1/1 slides · 2 hits 100% 1/1 slides Agitate 2 slides 100% 2/2 slides 100% 2/2 slides · 12 hits — 0/2 slides
— 0/2 slides
100% 2/2 slides 100% 2/2 slides 100% 2/2 slides Solution 6 slides 100% 6/6 slides 100% 6/6 slides · 35 hits — 0/6 slides
16.7% 1/6 slides 83.3% 5/6 slides · 6 hits 100% 6/6 slides · 7 hits 66.7% 4/6 slides Market Size 1 slides 100% 1/1 slides 100% 1/1 slides · 9 hits — 0/1 slides
100% 1/1 slides — 0/1 slides
100% 1/1 slides 100% 1/1 slides Slide inventory
56 every slide · same image gating as the playbook
03
The slide uses a three-column layout for strategic pillars followed by a bottom section highlighting clinical performance metrics.summarize
04
The slide uses a grid-based layout to categorize team members into three distinct organizational tiers.other
05
The slide uses a Gantt-style chart to represent clinical trial stages.plan_implementation
06
The slide uses a visual arrow graphic to imply forward momentum.plan_implementation
07
The slide uses a structural diagram to map technical modifications to clinical outcomes.present_solution
Open slide detailBeat · Solution
08
The slide uses a comparison framework to contrast standard industry benchmarks with the company's clinical data.compare_peers
Open slide detailBeat · Solution
09
The slide uses a process flow diagram to connect cellular pathology to clinical organ damage.frame_problem
10
Includes a biological pathway diagram showing B-cell maturation and a pyramid diagram showing the hierarchy of disease targeting.present_solution
11
Includes a biological process diagram showing the interaction between NXC-201 CAR-T cells and disease-causing LLPC clones.present_solution
12
Includes dot plot for BCMA expression, bar chart for IFNy activation, and flow cytometry plots showing cell elimination.present_solution
13
Uses a bar chart to compare CRS duration in days across four competitors, with NXC-201 highlighted as significantly lower.compare_peers
14
The slide uses a bar chart to compare neurotoxicity percentages and a table to compare clinical metrics like CRS onset and duration.compare_peers
15
The slide highlights NXC-201's 100% overall response rate and superior cardiac response compared to CAEL-101 and Birtamimab.compare_peers
Open slide detailLoop · Cost Of Inaction
16
The chart is a swimmer plot showing patient response duration, with an annotation indicating the target population for future enrollment.show_traction
Open slide detailLoop · Quick Win Big Bet
17
The slide uses a visual comparison between existing standard-of-care treatments (left) and the NXC-201 opportunity (center/right).size_opportunity
18
N-GENIUS TECHNOLOGY PLATFORM; NEXICART-1 Clinical Trial Data.show_traction
Open slide detailLoop · Quick Win Big Bet
19
Includes comparative data points for transduction efficiency and experimental data for tonic signaling and exhaustion.present_solution
Open slide detailLoop · Quick Win Big Bet
20
Includes citations from Nature Medicine and Signal Transduction and Targeted Therapy to validate the scientific approach.present_solution
Open slide detailLoop · Quick Win Big Bet
21
Uses a combination of bar charts for preclinical data and a comparison table for clinical outcomes to demonstrate the superiority of the CD8 hinge optimization.present_solution
Open slide detailLoop · Quick Win Big Bet
22
The slide uses a schematic to compare HSL and LSH configurations, showing superior performance for HSL in expansion and cytotoxicity metrics.present_solution
Open slide detailLoop · Quick Win Big Bet
23
Includes a footnote citing FDA approval precedents for single-arm studies.plan_implementation
Open slide detailLoop · Quick Win Big Bet
25
The slide uses a comparative diagram to show structural differences between NXC-201 and Abecma.present_solution
26
The diagram shows a summation of two patient groups (prevalence and incidence-derived relapsed/refractory) to reach a total eligible patient count.size_opportunity
27
The slide uses a molecular biology diagram to illustrate structural differences in binding domains and intracellular signaling components.present_solution
28
The slide uses a visual comparison of three treatment timelines to highlight the superior safety profile of NXC-201.compare_peers
29
The table compares NXC-201 against Darzalex, CAEL-101, and Birtamimab across various clinical metrics.compare_peers
30
Uses a before-and-after framing to illustrate market expansion potential.size_opportunity
31
The slide uses a structural layout to map platform capabilities to specific therapeutic products.present_solution
33
Includes a process diagram illustrating the medical procedure and a list of key attributes.present_solution
34
Includes a comparative table of clinical outcomes (ORR, CR/sCR) for NXC-201 vs competitors.argue_timing
35
The table highlights low incidence of severe adverse events and management protocols for NXC-201.analyze_data
36
The slide highlights safety data (CRS and ICANS) and toxicity management interventions.compare_peers
37
NXC-201 is highlighted with an orange border to emphasize its specific regimen.compare_peers
38
The table compares clinical trial inclusion criteria across four different therapies for relapsed/refractory multiple myeloma.compare_peers
39
Highlights NXC-201's competitive advantage regarding prior BCMA therapy exclusion.compare_peers
41
The slide uses cross-trial comparison; disclaimer notes these are not head-to-head results.compare_peers
43
The slide uses a segmented horizontal axis to compare two distinct market segments by revenue.size_opportunity
44
The slide uses a hub-and-spoke style diagram to link the platform pillars to specific drug candidates.present_solution
45
Slide contains three distinct data charts and a summary of clinical trial plans.show_traction
46
Includes three distinct proof-of-concept data panels (penetration, biodistribution, apoptosis).present_solution
47
Includes waterfall chart and longitudinal line charts for patient cohorts.show_traction
48
The slide uses a bubble chart to show clinical trial outcomes and a table to detail efficacy/safety metrics across treatment lines.frame_problem
49
The slide uses a combination of a conceptual chart and a data table to demonstrate efficacy and safety in heavily pre-treated patients.show_traction
50
Includes survival curves, bioluminescence imaging of mice, and tumor frequency metrics.show_traction
51
The slide uses a standard biological signaling pathway map to demonstrate the mechanism of action of the drug candidate.present_solution
53
Includes a comparison of iMX-111 size vs IgG antibody, GLUT1 expression across tissues, correlation with cancer stage, and a survival curve.present_solution
54
The slide uses a combination of mechanism diagrams, clinical trial bar charts, and preclinical mouse model data to validate the therapeutic approach.present_solution
55
The slide uses a bar chart comparison to establish a benchmark for clinical efficacy in the IBD market.compare_peers